会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • TAXOL ENHANCER COMPOUNDS
    • TAXOL增强剂化合物
    • WO2003006428A1
    • 2003-01-23
    • PCT/US2002/021714
    • 2002-07-10
    • SBR PHARMACEUTICALS CORP.KOYA, KeizoSUN, LijunCHEN, ShoujunTATSUTA, NoriakiWU, YamingONO, MitsunoriXIA, Zhi-Qiang
    • KOYA, KeizoSUN, LijunCHEN, ShoujunTATSUTA, NoriakiWU, YamingONO, MitsunoriXIA, Zhi-Qiang
    • C07C327/56
    • C07D307/68A45D2008/006A61K31/337A61K31/505A61K31/53A61K31/5377A61K47/58C07C327/56C07C2601/02C07C2601/04C07C2601/08C07C2601/14C07D209/42C07D209/44C07D213/83C07D261/18C07D333/38C07D333/68
    • One embodiment of the present invention is a compound represented by Structural Formula (I) wherein Y is a covalent bond of a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C=Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or -C(R 7 R 8 )-. R 1 is an aliphatic group, a substituted aliphatic group, a non-aromatic hetereocyclic group, or a substituted non-aromatic hetereocyclic group, R 2 -R 4 are independently -H, an aliphatic group, a substituted aliphatic group, a non-aromatic hetereocyclic group, a substituted non-aromatic hetereocyclic group, an aryl group or a substituted aryl group, or R 1 and R 3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R 2 and R 4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. R 5 -R 6 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R 7 and R 8 are each independently -H, an aliphatic or substituted aliphatic group, or R 7 is -H and R 8 is a substituted or unsubstituted aryl group, or, R 7 and R 8 , taken together, are a C2-C6 substituted or unsubstituted alkylene group. Z is =0 or =S. Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent.
    • 本发明的一个实施方案是由结构式(I)表示的化合物,其中Y是取代或未取代的直链烃基的共价键。 此外,Y与它所键合的两个> C = Z基团一起是取代或未取代的芳族基团。 优选Y为共价键或-C(R 7 R 8) - 。 R1是脂肪族基团,取代脂肪族基团,非芳香族杂环基团或取代的非芳香族杂环基团,R2-R4独立地是-H,脂肪族基团,取代的脂肪族基团,非芳香族的杂环基团 ,取代的非芳香族杂环基团,芳基或取代的芳基,或者R 1和R 3与它们所键合的碳原子和氮原子一起,和/或R 2和R 4与碳和氮原子一起 形成与芳环稠合的非芳族杂环。 R5-R6独立地是-H,脂族基团,取代的脂族基团,芳基或取代的芳基。 R 7和R 8各自独立地为-H,脂族或取代的脂族基团,或者R 7为-H且R 8为取代或未取代的芳基,或者R 7和R 8一起为C 2 -C 6取代或未取代的亚烷基 。 Z = 0或= S。 还公开了包含本发明化合物和药学上可接受的载体或稀释剂的药物组合物。
    • 3. 发明申请
    • PYRIMIDINE COMPOUNDS
    • 嘧啶化合物
    • WO2003047516A2
    • 2003-06-12
    • PCT/US2002/038161
    • 2002-11-27
    • SYNTA PHARMACEUTICALS CORPORATIONONO, MitsunoriSUN, LijunPRZEWLOKA, TeresaZHANG, ShijieKOSTIK, ElenaYING, WeiwenWADA, YumikoKOYA, KeizoWU, YamingZHOU, DanTATSUTA, Noriaki
    • ONO, MitsunoriSUN, LijunPRZEWLOKA, TeresaZHANG, ShijieKOSTIK, ElenaYING, WeiwenWADA, YumikoKOYA, KeizoWU, YamingZHOU, DanTATSUTA, Noriaki
    • A61K
    • C07D239/48A61K31/5377A61K31/541C07D401/12C07D401/14C07D403/12
    • This invention features pyrimidine compounds of formula (I): R 1 is formula (II), aryl, or heteroaryl; each of R 2 and R 4 , independently, is R c , halogen, nitro, cyano, isothionitro, SR c , or OR c ; or R 2 and R 4 , taken together, is carbonyl; R 3 is R c , alkenyl, alkynyl, OR c , OC(O)R c , S0 2 R c , S(O)R c , S(0 2 )NR c R d , SR c , NR c R d , NR c COR d , NR c C(O)OR d , NR c C(O)NR c R d , NR c S0 2 R d , COR c , C(O)OR c , or C(O)NR c R d ; R 5 is H or alkyl; n is 0, 1, 2, 3, 4, 5, or 6; X is O, S, S(O), S(0 2 ), or NR c ; Y is a covalent bond, CH 2 , C(O), C=N-R c , C=N-OR c , C=N-SR c , O, S, S(O), S(0 2 ), or NR c ; Z is N or CH; one of U and V is N, and the other is CR c ; and W is O, S, S(O), S(0 2 ), NR c , or NC(O)R c ; in which each of R a and R b , independently, is H, alkyl, aryl, heteroaryl; and each of R c and R d , independently, is H, alkyl, aryl, heteroaryl, cyclyl, heterocyclyl, or alkylcarbonyl. The compounds are useful for treating IL-12 overproduction related diseases (e.g., rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis, or insulin-dependent diabetes mellitus).
    • 本发明的特征是式(I)的嘧啶化合物:R1是式(II),芳基或杂芳基; 每个R 2和R 4独立地为R c,卤素,硝基,氰基,异硫氰酸根,SR c, sup>或OR c ; 或者R 2和R 4合在一起为羰基; R 3是R c,烯基,炔基,OR c,OC(O)R c,S 0, (O)R c,S(O 2)NR c,其中R 1,R 2, R c,NR c,NR c,NR c,NR c,NR c,NR c R c, (O)OR d,NR c C(O)NR s,C(O)NR c, R c,R c,R c,R c,R c,R c,R c,R c,R c,R c, C(O)OR c或C(O)NR c R d; R 5是H或烷基; n是0,1,2,3,4,5或6; X是O,S,S(O),S(O 2)或NR C; Y是共价键,CH 2,C(O),C = NR c,C = N-OR c,C = N -S(O)S,S(O),S(O 2)或NR C; Z是N或CH; U和V中的一个是N,另一个是CR c ; 和W是O,S,S(O),S(O 2),NR C或NC(O)R C; 其中R a和R b各自独立地为H,烷基,芳基,杂芳基; 并且每个R c和R d独立地为H,烷基,芳基,杂芳基,环基,杂环基或烷基羰基。 该化合物可用于治疗IL-12过量产生相关疾病(例如类风湿性关节炎,败血症,克罗恩氏病,多发性硬化症,牛皮癣或胰岛素依赖性糖尿病)。